Citations

Clear

634 citation(s) found for "Hall, A".

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, Martin S. , Wang, Eunice S. , Altman, Jessica K. , Appelbaum, Frederick R. , Bixby, Dale L. , Coutré, Steven , Fathi, Amir T. , Fiorella, Melanie, Foran, James M. , Hall, Aric C. , Jacoby, Meagan A., LeBlanc, Thomas W. , Mannis, Gabriel N. , Marcucci, Guido , Martin, Michael G. , O’Donnell, Margaret, Olin, Rebecca L. , Peker, Deniz , Perl, Alexander E. , Pratz, Keith W. , Shami, Paul J. , Stone, Richard M. , Strickland, Stephen A. , Wieduwilt, Matthew J. , Gregory, Kristina M., OCN, Hammond, Lydia J., Ogba, Ndiya , Wang, Eunice S. , Strickland, Stephen Anthony , Leblanc, Thomas , Bhatt, Vijaya Raj , Lima, Marcos de , Lancet, Jeffrey E. , Mims, Alice S , Pollyea, Daniel Aaron , Prébet, Thomas , Ravandi, Farhad , OCN

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 721-749

10.6004/jnccn.2019.0028 | PMID 31200351 Get It

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).
Bergsland, Emily K. , Mahoney, Michelle R., Asmis, Timothy R., Kumthekar, Priya , Niedzwiecki, Donna , Schwartz, Lawrence H., Niedzwiecki, Donna , Hall, Nathan C. , Maitland, Michael L. , Nixon, Andrew B. , O’Reilly, Eileen M. , Strosberg, Jonathan , Meyerhardt, Jeffrey A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2019.37.15_suppl.4005 Get It

4005 Background: Patients (pts) with progressive advanced well-differentiated neuroendocrine tumors arising outside of the pancreas have limited systemic treatment options. Pazopanib (PZ) is an oral multi-kinase inhibitor with activity against VEGFR-2,-3, PDGFR-α, and β, and c-KIT, with initial data suggesting efficacy in CARC. Methods: This was a multicenter, randomized, double-blind, phase II study of PZ (800 mg/day) versus placebo (PL) in progressive CARC. Key eligibility: low-intermediate grade CARC, radiologic progressive disease (PD) < 12 months (mo), and adequate end-organ function. Prior somatostatin analog (SSA) mandated for midgut tumors. Concurrent SSA allowed if previous PD on SSA documented. Primary endpoint was progression-free survival (PFS), defined as time from randomization to PD by central review or death. Secondary endpoints included overall survival (OS), objective response rate (ORR) and safety. The trial had 85% power to detect a difference in median PFS of 14 v 9 mo (hazard ratio [HR] 0.64) at one-sided alpha = 0.1. A stratified log-rank test based on the intend-to-treat (ITT) principle was used. Unblinding and crossover were allowed if PD confirmed by central review. Results: 171 (97 PZ, 74 PL) pts were randomized between 6/2013-10/2015: median age 63; 56% female; 66% small bowel primary; 87% concurrent SSA. Median follow-up of 31 mo; 112 (56 PZ, 56 PL) PFS events observed. 6 pts (4 PZ, 2 PL) remain on initial treatment. Median PFS was 11.6 and 8.5 mo in PZ and PL, respectively (HR = 0.53, 1-sided 90% upper confidence limit [UCL] 0.69, p = 0.0005) which crossed the pre-specified protocol efficacy boundary. 49 PL pts received PZ after PD. Median OS was 41 and 42 mo in PZ and PL, respectively (HR = 1.13, 1-sided 90% UCL 1.51, p = 0.70). RR data will be presented. Notable grade 3+ adverse events were (PZ v. PL %) hypertension (35 v. 8), fatigue (11 v. 4), ALT (10 v. 0), AST (10 v. 0), and diarrhea (7 v. 4). Conclusions: PZ compared to PL was associated with significant improvement in PFS in patients with progressive CARC. The results confirm that VEGF signaling pathway is a valid target for therapy in CARC. Support: U10CA180821, U10CA180882 https://acknowledgments.alliancefound.org . Clinical trial information: NCT01841736.
Airway Obstruction in a Patient After Kidney Transplant
Hall, S. , Mecham, Jeffrey C. , Hall, S Ryan, Lott, David G.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 9, 2019 | Volume: 145 | Issue: 7 | Pages: 680

10.1001/jamaoto.2019.0772 | PMID 31070696 Get It

Association of peripheral artery disease with in‐hospital outcomes after endovascular transcatheter aortic valve replacement
Mohananey, Divyanshu , Villablanca, Pedro , Ando, Tomo , Wang, Dee Dee , Wiley, José , Eng, Marvin H. , Shah, Binita , Saucedo, Jorge , Bhatt, Deepak L. , Ando, Tomo , Wang, Dee Dee , Eng, Marvin , Ramakrishna, Harish , Bhatt, Deepak L , Shah, Binita , Gupta, Tanush , Ranka, Sagar , Bhatia, Nirmanmoh , Adegbala, Oluwole Muyiwa , Kalra, Ankur , O’Neill, William W.

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 26, 2019 | Volume: 94 | Issue: 2 | Pages: 249-255

10.1002/ccd.28310 | PMID 31025488 Get It

AbstractObjectivesThe aim of this study was to determine the prevalence of peripheral artery disease (PAD) and its association with in‐hospital outcomes after endovascular transcatheter aortic valve replacement (EV‐TAVR).BackgroundTAVR is an established treatment for patients at prohibitive, high, or intermediate surgical risk. PAD is a significant comorbidity in the determination of surgical risk. However, data on association of PAD with outcomes after EV‐TAVR are limited.MethodsPatients in the National Inpatient Sample who underwent EV‐TAVR between January 1, 2012 and September 30, 2015 were evaluated. The primary outcome was in‐hospital mortality.ResultsA total of 51,685 patients underwent EV‐TAVR during the study period. Of these, 12,740 (24.6%) had a coexisting diagnosis of PAD. The adjusted odds for in‐hospital mortality [OR 1.08 (95% CI 0.83–1.41)], permanent pacemaker implantation [OR 0.98 (0.85–1.14)], conversion to open aortic valve replacement [OR 1.05 (0.49–2.26)], or acute myocardial infarction [OR 1.31(0.99–1.71)] were not different in patients with versus without PAD. However, patients with PAD had greater adjusted odds of vascular complications [OR 1.80 (1.50–2.16)], major bleeding [OR 1.20 (1.09–1.34)], acute kidney injury (AKI) [OR 1.19 (1.05–1.36)], cardiac complications [aOR 1.21 (1.01–1.44)], and stroke [OR 1.39(1.10–1.75)] compared with patients without PAD. Length of stay (LOS) was significantly longer for patients with PAD [7.23 (0.14) days vs. 7.11 (0.1) days, p < 0.001].ConclusionOf patients undergoing EV‐TAVR, ~25% have coexisting PAD. PAD was not associated with increased risk of in‐hospital mortality but was associated with higher risk of vascular complications, major bleeding, AKI, stroke, cardiac complications, and longer LOS.
Repeatability of linear and nonlinear quantitative compression elastography in the breast
Barbone, Paul E. , Gendin, Daniel , Wang, Yuqi , Nayak, Rohit , Oberai, Assad A. , Hall, Timothy J. , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

The Journal of the Acoustical Society of America | April 24, 2019 | Volume: 145 | Issue: 3_Supplement | Pages: 1891-1891

10.1121/1.5101854 Get It

Compression elastography allows the precise measurement of large deformations of soft tissue in vivo. From a measured large deformation, an inverse problem for both the linear and nonlinear elastic moduli distributions can be solved. As part of a larger clinical study to evaluate NEMs in breast cancer, we evaluate the repeatability of linear and nonlinear modulus maps from repeat measurements. Within the cohort of 31 subjects scanned to date, several had repeated scans. These repeated scans were processed to evaluate NEM repeatability. In vivo data were acquired by a custom, digitally controlled, uniaxial compression device with force feedback. RF-data were acquired using plane wave imaging, at a frame-rate of 200 Hz, with a ramp-and-hold compressive force of 8N, applied at 8 N/s. A two-dimensional (2D) block-matching algorithm was used to obtain sample-level displacement fields which were then tracked at subsample resolution using 2D cross correlation. Linear and nonlinear elasticity parameters in the Blatz model of tissue elasticity are estimated using iterative optimization. Repeatability between both modes and elastic modulus maps is measured and compared. Preliminary results indicate that when images are acquired in the same region of tissue, the modulus maps are consistent. [Work supported by NIH R01CA195527.]
Targeting the C5 subclass of high-grade serous ovarian cancer using patient-derived xenografts: Microtubule polymerisation inhibitors.
Heong, Valerie , Topp, Monique, Ananda, Sumitra, McNally, Orla , Lindeman, Geoffrey John, Ruby, Huang, Haluska, Paul , Wakefield, Matthew J. , Swisher, Elizabeth M. , Tan, David S.P. , Bowtell, David D.L. , Scott, Clare L.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e22202-e22202

10.1200/jco.2015.33.15_suppl.e22202 Get It

American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems
Hall, S. , Neel, Gregory S., Howard, Brittany E. , Nagel, Thomas H. , Hayden, Richard E. , Hinni, Michael L., Hall, Scott R , Chang, Brent A. , Lott, David G. , Zhang, Nan

Mayo Clinic

Head & Neck | April 2, 2019 | Volume: 41 | Issue: 8 | Pages: 2716-2723

10.1002/hed.25749 | PMID 30939209 Get It

AbstractBackgroundThe American Joint Committee on Cancer (AJCC) eighth edition introduces a staging system specific for human papilloma virus positive oropharyngeal cancer with separate clinical (AJCC 8c) and pathological (AJCC 8p) criteria.MethodsIn this retrospective cohort study, preoperative imaging and pathology reports were used to stage patients based on the AJCC 8c and AJCC 8p criteria, respectively. The primary endpoint was agreement between AJCC 8c and AJCC 8p.ResultsA total of 213 patients met inclusion criteria. Kappa statistics showed poor agreement (κ = 0.3275) between AJCC 8c and AJCC 8p. In total, 30.3% of patient's preoperative AJCC 8c stage changed based on the postoperative pathologic staging (AJCC 8p) with 73.4% of those being upstaged.ConclusionThese data suggest that disagreement exists between AJCC 8c and AJCC 8p, in part due to the separate clinical and pathological staging criteria. This discrepancy should be considered as the new system is implemented.
Outcomes of orthotopic heart transplantation and left ventricular assist device in patients aged 65 years or more with end-stage heart failure
Harmon, David , Tecson, Kristen M. , Jamil, Aayla K. , Felius, Joost , Gonzalez‐Stawinski, Gonzalo V. , Joseph, Susan , Hall, Shelley , Harmon, David M , Hall, Shelley A

Mayo Clinic

Baylor University Medical Center Proceedings | March 28, 2019 | Volume: 32 | Issue: 2 | Pages: 177-180

10.1080/08998280.2019.1576095 | PMID 31191122 Get It

Predicting Cigarette Initiation and Reinitiation among Active Duty United States Air Force Recruits
Little, Melissa A. , Ebbert, Jon O. , Krukowski, Rebecca A. , Halbert, Jennifer P. , Kalpinski, Ryan J. , Patten, Christi A. , Boothe, Tina, Pasker, Christin, Klesges, Robert C. , Talcott, G. Wayne , Patten, Christi

Mayo Clinic

Substance Abuse | March 18, 2019 | Volume: 40 | Issue: 3 | Pages: 340-343

10.1080/08897077.2019.1577678 | PMID 30883297 Get It

Background The first year of military service in the United States Air Force (USAF) is a high-risk time for tobacco use. Previous studies have demonstrated the effectiveness of a tobacco ban during Basic Military Training (BMT). However, no studies have examined the effect of increasing the protracted ban for an additional 4 weeks. Understanding the patterns of initiation and reinitiation following the protracted ban will inform future intervention and policy efforts. Methods The current study examines patterns of cigarette smoking among a sample of 2188 USAF personnel at baseline and after their first year of service. Results One year after BMT, we observed that 65.0% of USAF enlistees remained never smokers, 9.6% remained abstinence from cigarettes, 9.3% initiated cigarette smoking, and 16.1% reinitiated cigarette smoking. Despite the extended tobacco ban in BMT and Technical Training, 12.6% of individual who never smoked initiated cigarette smoking and 62.6% of individuals who formerly smoked reinitiated. Over half (54.2%) of Airmen who reported smoking cigarettes at follow-up reported initiating or reinitiating during Technical Training. Conclusions Our findings indicate that although the increased ban prevents additional individuals who smoked cigarettes prior to joining the Air Force from reinitiating, it has no effect on initiation among individuals who report never using prior to military service. Additional research is needed to understand what may be leading to these high rates of initiation and reinitiation in Technical Training following the ban.
A proteomic signature for dementia with Lewy bodies
Ferman, Tanis J. , Hall, James , Pedraza, Otto , Como, Tori, Julovich, David, Mattevada, Sravan, Graff‐Radford, Neill R., Zhang, Fan , Ferman, Tanis J , O’Bryant, Sid E. , Zhang, Fan , Wszołek, Zbigniew K. , Johnson, Leigh , Edwards, Melissa , Graff‐Radford, Neill R.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | March 14, 2019 | Volume: 11 | Issue: 1 | Pages: 270-276

10.1016/j.dadm.2019.01.006 | PMID 30923734 Get It

AbstractIntroductionWe sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD).MethodsStored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols.ResultsIn the first step, the proteomic profile distinguished the DLB‐PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88.DiscussionThese data provide evidence of the potential utility of a multitiered blood‐based proteomic screening method for detecting DLB and distinguishing DLB from PD.